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Abstract: Background: Epstein–Barr virus (EBV) and cytomegalovirus (CMV) infections can have
serious consequences during the period of aplasia and lymphopenia following hematopoietic stem
cell transplantation (HSCT). Large pediatric cohort studies examining the effect of antiviral prophy-
laxis against these viruses are scarce. The present study aimed to analyse the potential effect of
antiviral prophylaxis (acyclovir and famciclovir) on active post-transplant EBV and CMV infection
in a pediatric cohort of allogeneic HSCT recipients. Methods: We used data from the TREASuRE
cohort, consisting of 156 patients who had a first allogeneic HSCT, enrolled in four pediatric centers
in Canada between July 2013 and March 2017. Follow-up was performed from the time of transplant
up to 100 days post-transplant. Adjusted hazard ratio (HR) with 95% confidence intervals (CI) for
the association between antiviral prophylaxis with acyclovir and/or famciclovir and EBV and CMV
DNAemia was estimated using multivariate Cox regression models. Results: The post-transplant
cumulative incidence of EBV and CMV DNAemia at 100 days of follow-up were, respectively, 34.5%
(95% CI: 27.6–42.6) and 19.9% (95% CI: 14.5–27.1). For acyclovir, the adjusted hazard ratio (HR) for
CMV and EBV DNAemia was 0.55 (95% CI: 0.24–1.26) and 1.41 (95% CI: 0.63–3.14), respectively. For
famciclovir, the adjusted HR were 0.82 (95% CI: 0.30–2.29) and 0.79 (95% CI: 0.36–1.72) for CMV and
EBV DNAemia, respectively. Conclusion: The antivirals famciclovir and acyclovir did not reduce the
risk of post-transplant CMV and EBV DNAemia among HSCT recipients in our pediatric population.
Vaccines 2021, 9, 610. https://doi.org/10.3390/vaccines9060610 https://www.mdpi.com/journal/vaccines
Vaccines 2021, 9, 610 2 of 12
Keywords: antiviral prophylaxis; hematopoietic stem cell transplantation; Epstein–Barr virus;
cytomegalovirus; human herpesvirus; pediatric
1. Introduction
Hematopoietic stem cell transplantation (HSCT) is used for the treatment of malignant
tumors and certain blood or immune system disorders [1–4]. The immunosuppressed
state correlates with a significant risk of post-transplant infections, and these infections
play a major role in treatment-related morbidity and post-transplant mortality in pediatric
HSCT [5–10]. Among the most morbid viral infections are those caused by the human
herpesviruses (HHV), namely herpes simplex viruses (HSV or HHV-1/2), varicella-zoster
virus (VZV or HHV-3), Epstein–Barr virus (EBV or HHV-4), and cytomegalovirus (CMV
or HHV-5) [11,12]. Active infection with HHV-6 (roseolavirus) and HHV-7 can also occur
but is less common [1,11–14]. HHV-8 infection (associated with Kaposi’s sarcoma and
Castleman’s disease) is infrequent in pediatric HSCT [15,16]. Active HHV infections
can occur either during primary infection or following reactivation of latent virus [8],
predominantly during the early post-transplant period when the patient’s cell-mediated
immune response is severely compromised [9–11]. More than two-thirds of patients
develop viral reactivation or primary HHV infections in the first 3 months after HSCT [12].
Antivirals are generally used systematically in clinical protocols to prevent reactivation
of specific human herpesviruses, namely HSV, VZV, and CMV [17–19]. The Francophone
Society of Bone Marrow Transplantation and Cell Therapy, and the European Conference
on Leukemia recommend prophylaxis for HSV seropositive patients from the start of
conditioning until the end of granulocytopenia and resolution of mucositis. Specific recom-
mendations involve the use of intravenous acyclovir or famciclovir for 3 to 6 weeks after
initiation of chemotherapy or grafting, or up to the end of aplasia [18,20]. Long-term pro-
phylaxis with acyclovir (up to one-year post-transplant or until immunosuppressive drugs
are discontinued) is also recommended for VZV seropositive HSCT recipients. Ganciclovir
is recommended until day 100 post-HSCT to prevent active CMV infection in allogeneic
HSCT recipients who are at risk (CMV seropositive recipient or CMV seropositive donor)
of engraftment failure [21,22]. Although active EBV infection is very common and may
lead to serious complications such as post-transplant lymphoproliferative disorder (PTLD),
the International Medical Societies do not recommend the use of antiviral prophylaxis for
EBV as there is no proven clinically effective antiviral against this virus [23].
Viral blood monitoring can also be done for early detection of viral DNA and pre-
emptive treatment. In this case, valaciclovir and famciclovir are preferred for the oral
treatment of HSV and VZV in pediatric HSCT recipients with stable localized disease [18].
Intravenous ganciclovir can also be used for the treatment of CMV disease during the year
following HSCT [21,22]. Although there are no recognized clinically effective antivirals
against EBV, qPCR monitoring is usually performed to assess pre-emptive treatment of
patients showing significant spikes in viral load with the anti-CD20 monoclonal (rituximab)
thereby preventing the development of PTLD [18].
Overall, the prophylactic efficacy of acyclovir and famciclovir for HSV and VZV is well
recognized as a standard-of-care in the clinical guidelines of various transplant societies.
However, questions remain about the potential effect of these antivirals on other HHV, such
as EBV and CMV. The pediatric literature on this issue is especially limited. The main goal
of this study was, therefore, to measure the association between antiviral prophylaxis with
acyclovir and famciclovir and post-transplant EBV and CMV DNAemia among pediatric
recipients of allogeneic HSCT.
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2. Methods
2.1. Study Design and Participants
We used data from TREASuRE study, a multicenter prospective cohort study of
allogeneic HSCT recipients from four Canadian pediatric tertiary care centers. Study
design and methods have been published previously [24]. Briefly, the study enrolled
156 patients under the age of 21 who had undergone allogeneic HSCT (bone marrow, cord
blood, or peripheral blood). Recruitment was conducted at different sites: CHU Sainte-
Justine in Montreal (n = 86), British Columbia Children’s Hospital of Vancouver (n = 31),
Winnipeg Children’s Hospital and CancerCare Manitoba (n = 28) and Alberta Children’s
Hospital (n = 11). Patients were recruited approximately one month before transplant
and followed up to one-year post-transplant for a maximum follow-up time of 13 months.
Recruitment and follow-up began in July 2013 and ended in March 2017. At entry, a case
report form (CRF) documented demographic data and pre-transplant clinical indicators
such as age, sex, primary diagnosis, previous chemotherapy, conditioning regimen, graft
source, donor type (matched or mismatched), EBV serology, and antiviral prophylaxis.
During follow-up, data were collected prospectively through CRFs for variables related to
diagnosed infections and treatment received. HHV DNAemia was diagnosed following
confirmed positive testing by polymerase chain reaction (PCR). Table S1 provides details
on the EBV and CMV qPCR tests used in each study site. Completed CRFs were sent
prospectively to the coordination center at Sainte-Justine Hospital and data were included
in the ACCESS database. This study protocol was approved by the research ethics boards
of all four participating institutions, with patient consent waived as all data used in this
analysis were collected through medical charts.
2.2. Statistical Analysis
Cumulative incidence (and 95% confidence interval (CI)) of EBV and CMV DNAemia
were estimated using the Kaplan–Meier method and compared according to the antivirals
(acyclovir and famciclovir) using log-rank testing. The curve for EBV DNAemia was strati-
fied according to the pre-transplant EBV serological status of recipients. Follow-up time
was considered from date of transplant up to the date of the EBV or CMV DNAemia event
or, for censored information, up to 100 days post-transplant. A proportional hazard Cox
regression model was used to measure the association between EBV and CMV DNAemia
and antiviral use (famciclovir or acyclovir). Adjusted hazard ratio (HR) and 95% CI were es-
timated. Confounding was empirically controlled using the 5% change in estimate method
for the following potential variables: age (continuous), primary diagnosis (malignant or
non-malignant), graft source (stem cell peripheral blood/bone marrow or cord blood),
conditioning regimen (myeloablative conditioning or other conditioning), sex (female or
male), donor match (alternative or matched related donor), recipient pre-transplant EBV
serology (negative, positive or unknown), graft donor EBV serostatus (negative, positive or
unknown), Graft-versus-host disease (GvHD) (yes or no), and for the use (yes or no) of
antithymocyte globulin (ATG), alemtuzumab, tacrolimus (FK506) or cyclosporine A (CsA),
methotrexate (MTX), and mycophenolate mofetil (MMF). Multivariate models included the
above-mentioned variables that changed the HR by ±5%. All analyses were done using
STATA statistical software, version 14.2 (StataCorp, College Station, TX, USA).
3. Results
Table 1 reports the characteristics of the 156 patients included in the TREASuRE study
according to the occurrence of post-transplant HHV DNAemia diagnosed during follow-
up. Of these, 79 (50.6%) had at least one active HHV episode throughout the follow-up
period (up to day 100 post-transplant) including 53 (34%) EBV episodes and 31 (19.9%)
CMV episodes. Only a few cases of HSV (n = 3), VZV (n = 1) and HHV-6 (n = 4) were
diagnosed. The post-transplant cumulative incidences of HSV, VZV, EBV, CMV, and HHV-6
DNAemia after 100 days of follow-up were, respectively, 2.5% (95% CI 0.8–7.6), 0.9% (95%
CI: 0.1–6.1), 34.5% (95% CI: 27.6–42.6), 19.9% (95% CI: 14.5–27.1), and 3.4% (95% CI: 1.2–9.1).
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The mean age at transplant for all patients included in the analysis was 7.3 years (standard
deviation (SD) ± 5.3). There were 117 patients (75%) treated with intravenous acyclovir
and 43 patients (27.6%) with famciclovir. No other antiviral was given to recipients except
for four patients who received ganciclovir (two who also received acyclovir and two
who received famciclovir). Table S2 provides the characteristics of subjects according to
antiviral use.
Table 1. Characteristics of HSCT recipients according to post-transplant HHV DNAemia.







Number of Patients (n) n = 156 n = 3 n = 1 n = 53 n = 31 n = 4 n = 77 n = 79
Sex, n (%) Male 83 (53.2) 2(66.7) 0 26 (49.1) 14 (45.2) 3 (75.0) 44 (57.1) 39 (49.4)
Female 73(46.8) 1(33.3) 1 (100) 27 (50.9) 17 (54.8) 1 (25.0) 33 (42.9) 40 (50.6)
Recipient age at transplant
(years)

















Primary diagnosis, n (%)
Malignant 69 (44.2) 1(33.3) 1 (100) 21 (39.6) 12 (38.7) 2 (50.0) 35 (45.5) 34 (43)
Non-
malignant 87 (55.8) 2(66.7) 0 32 (60.4) 19 (61.3) 2 (50.0) 42 (54.5) 45 (57)
Recipient pre-transplant
EBV serology, n (%)
Negative 42 (26.9) 0 0 8 (15.1) 8 (25.8) 1 (25.0) 26 (33.8) 16 (20.3)
Positive 101(64.8) 3(100) 1 (100) 40 (75.5) 21 (67.7) 3 (75.0) 43 (55.8) 58 (73.4)
Unknown 13 (8.3) 0 0 5 (9.4) 2 (6.5) 0 8 (10.4) 5 (6.3)
Graft EBV serostatus, n (%)
Negative 62 (39.7) 2 (66.7) 1 (100) 8 (15.1) 12 (38.7) 3 (75.0) 39 (50.6) 23 (29.1)
Positive 63 (40.4) 1 (33.3) 0 32 (60.4) 15 (48.4) 1 (25.0) 20 (26) 43 (54.4)
Unknown 31 (19.9) 0 0 13 (24.5) 4 (12.9) 0 18 (23.4) 13 (16.5)
Donor match, n (%)
Donor
matched 53 (34.0) 0 1 (100) 18 (34.0) 14 (45.2) 0 28 (36.4) 25 (31.6)
Alternative
donor 103 (66.0) 3 (100) 0 35 (66.0) 17 (54.8) 4 (100) 49 (63.6) 54 (68.4)
Graft source, n (%) CB 39 (25.0) 2 (66.7) 0 5 (9.4) 9 (29.0) 3 (75.0) 23 (29.9) 16 (20.3)
BM/PBSC 117 (75.0) 1 (33.3) 1 (100) 48 (90.6) 22 (71.0) 1 (25.0) 54 (70.1) 63 (79.7)
GvHD, n (%)
No 97 (62.18) 1 (33.33) 1 (100) 34 (64.15) 23 (74.19) 0 51 (66.23) 46 (58.23)
Yes 59 (37.82) 2 (66.67) 0 19 (35.85) 8 (25.81) 4 (100) 26 (33.77) 33 (41.77)
Conditioning regimen, n (%) Other 98 (62.8) 2 (66.7) 0 35 (66.0) 18 (58.1) 1 (25.0) 50 (64.9) 48 (60.8)
MAC 58 (37.2) 1 (33.3) 1 (100) 18 (34.0) 13 (41.9) 3 (75.0) 27 (35.1) 31 (39.2)
Antithymocyte globulin, n
(%)
No 92 (59.0) 3 (100) 1 (100) 19 (35.8) 19 (61.3) 3 (75.0) 52 (67.5) 40 (50.6)
Yes 64 (41.0) 0 0 34 (64.2) 12 (38.7) 1 (25.0) 25 (32.5) 39 (49.4)
Alemtuzumab, n (%)
No 118(75.6) 1 (33.3) 1 (100) 44 (83.0) 24 (77.4) 3 (75.0) 55 (71.4) 63 (79.7)
Yes 38 (24.4) 2 (66.7) 0 9 (17.0) 7 (22.6) 1 (25.0) 22 (28.6) 16 (20.3)
Tacrolimus or CsA, n (%) No 15 (9.6) 0 0 3 (5.7) 3 (9.7) 2 (50.0) 8 (10.4) 7 (8.9)
Yes 141(90.4) 3 (100) 1 (100) 50 (94.3) 28 (90.3) 2 (50.0) 69 (89.6) 72 (91.1)
MTX, n (%)
No 92 (59.0) 1 (33.3) 0 23 (43.4) 18 (58.1) 3 (75.0) 52 (67.5) 40 (50.6)
Yes 64 (41.0) 2 (66.7) 1 (100) 30 (56.6) 13 (41.9) 1 (25.0) 25 (32.5) 39 (49.4)
MMF, n (%)
No 100(64.1) 2 (66.7) 1 (100) 46 (86.8) 21 (67.7) 2 (50.0) 39 (50.6) 61 (77.2)
Yes 56 (35.9) 1 (33.3) 0 7 (13.2) 10 (32.3) 2 (50.0) 38 (49.4) 18 (22.7)
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Table 1. Cont.







Number of Patients (n) n = 156 n = 3 n = 1 n = 53 n = 31 n = 4 n = 77 n = 79
Acyclovir, n (%)
No 39 (25.0) 0 1 (100) 9 (17.0) 10 (32.3) 0 21 (27.3) 18 (22.8)
Yes 117(75.0) 3 (100) 0 44 (83.0) 21 (67.7) 4 (100) 56 (72.7) 61 (77.2)
Famciclovir, n (%)
No 113(72.4) 2 (66.7) 1 (100) 39 (73.6) 24 (77.4) 4 (100) 54 (70.1) 59 (74.7)
Yes 43 (27.6) 1 (33.3) 0 14 (26.4) 7 (22.6) 0 23 (29.9) 20 (25.3)
Other antivirals
(Ganciclovir) n (%)
No 152(97.44) 2 (66.67) 1 (100) 52 (98.11) 28 (90.32) 4 (100) 75 (94.94) 77 (100)
Yes 4 (2.56) 1 (33.33) 0 1 (1.89) 3 (9.68) 0 4 (5.06) 0
ATG: antithymocyte globulin; BM: bone marrow; CB: cord blood; CsA: cyclosporine A; CMV: cytomegalovirus; EBV: Epstein–Barr virus;
GvHD: Graft-versus-host disease; HHV: human herpesvirus; HHV-6: human herpesvirus 6; HSV-1: herpes simplex virus 1; HSCT:
hematopoietic stem cell transplant; IQR: interquartile range; MAC: myeloablative conditioning; MMF: mycophenolate mofetil; MTX:
methotrexate; NA: not applicable; PBSC: peripheral blood stem cells; SD: standard deviation; VZV: varicella-zoster virus.
Figures 1 and 2 illustrate the cumulative incidence of CMV and EBV DNAemia
in transplant recipients according to antiviral treatment. Table 2 shows the estimates
for associations between antivirals (acyclovir or famciclovir) and post-transplant EBV
and CMV DNAemia. There was no significant difference between patients on antiviral
treatment versus untreated. The adjusted HR for the relationship between acyclovir
and EBV and CMV DNAemia were respectively 1.41 (95% CI: 0.63–3.14) and 0.55 (95% CI:
0.24–1.26). For famciclovir, the adjusted HR for EBV and CMV DNAemia were, respectively,
0.80 (95% CI: 0.42–1.51) and 0.82 (95% CI: 0.30–2.29).
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Figure 1. Cumulative incidence of CMV DNAemia according to acyclovir or famciclovir use. All patients (n = 156),
CMV: cytomegalovirus.
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Figure 2. Cumulative incidence of EBV DNAemia according to acyclovir and famciclovir use. All patients (n = 156). EBV: 
Epstein–Barr virus. 
Table 2. Hazard ratios for the associations between antiviral prophylaxis (acyclovir or famciclovir) and post-transplant 
EBV and CMV DNAemia 
Variable Number of Cases Person-Time (Months) Incidence Rate (95% CI) HR Crude (95% CI) 
HR Adjusted 
(95% CI) 
EBV DNAemia  53 406.87 0.13 (0.1–0.17)   
Acyclovir (a) 
No 9 106.28 0.08 (0.04–0.16) 1 1 
Yes 44 300.58 0.15 (0.11–0.20) 1.68 (0.82–3.44)1.41 (0.63–3.14) 
Famciclovir (b) 
No 39 287.61 0.14 (0.10–0.19) 1 1 
Yes 14 119.26 0.12 (0.07–0.20) 0.85 (0.46–1.58)0.79 (0.36–1.72)
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EBV DNAemia 53 406.87 0.13 (0.1–0.17)
Acyclovir (a)
No 9 106.28 0.08 (0.04–0.16) 1 1
Yes 44 300.58 0.15 (0.11–0.20) 1.68 (0.82–3.44) 1.41 (0.63–3.14)
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Table 2. Cont.








No 39 287.61 0.14 (0.10–0.19) 1 1
Yes 14 119.26 0.12 (0.07–0.20) 0.85 (0.46–1.58) 0.79 (0.36–1.72)
CMV DNAemia 31 425.95 0.07 (0.05–0.10)
Acyclovir (c)
No 10 100.47 0.10 (0.05–0.18) 1 1
Yes 21 325.49 0.06 (0.04–0.10) 0.64 (0.30–1.36) 0.55 (0.24–1.26)
Famciclovir (d)
No 24 304.23 0.08 (0.05–0.12) 1 1
Yes 7 121.72 0.06 (0.03–0.12) 0.77 (0.33–1.78) 0.82 (0.30–2.29)
CMV: cytomegalovirus; EBV: Epstein–Barr virus; HR: hazard ratio; CI: Confidence intervals. (a) The following variables were considered
to estimate the adjusted hazard ratio: recipient age at transplant (continuous), recipient pre-transplant EBV serology (negative, positive
or unknown), graft donor EBV serostatus (negative, positive or unknown), antithymocyte globulin (yes or no) and site of study. (b) The
following variables were considered to estimate the adjusted hazard ratio: recipient age at transplant (continuous), recipient pre-transplant
EBV serology (negative, positive or unknown), graft source (bone marrow/peripheral blood stem cells or cord blood), conditioning regimen
(myeloablative or other), anti-thymocyte globulin (yes or no), mycophenolate mofetil (yes or no) and site of study. (c) The following
variables were considered to estimate the adjusted hazard ratio: recipient sex (female or male) and recipient pre-transplant EBV serology
(negative, positive, or unknown). (d) The following variables were considered to estimate adjusted hazard ratio: graft donor EBV serostatus
(negative, positive or unknown), donor match (alternative or matched related donor), conditioning regimen (myeloablative or other) and
site of study.
4. Discussion
In this study, we found no statistically significant protective effect of acyclovir or
famciclovir prophylaxis on EBV and CMV DNAemia incidence in our HSCT pediatric
population. Other herpesvirus infections were infrequent with less than 5% cumulative
incidence. Only three patients had HSV infection within 100 days post-transplant. The
efficacy of acyclovir in the prophylaxis of HSV among seropositive patients has been
demonstrated previously [20,25,26].
There was only one case of VZV infection in our cohort of 156 HSCT patients. The
efficacy of acyclovir in the prevention of VZV reactivation has also been shown in numerous
prior studies [20,24–33]. Moreover, universal vaccination against VZV with an attenuated
wild strain, recommended since 1999 in all Canadian provinces [34], has also likely reduced
wild-type VZV exposure in our cohort.
CMV reactivation is common after allogeneic HSCT [32]. In our cohort, the cu-
mulative incidence of CMV DNAemia at 100 days post-transplant was 19.9% (95% CI:
14.5–27.1), while it ranged from 21.8% to 24% within four months in similar pediatric HSCT
studies [6,35,36]. Importantly, in our study, the incidence of CMV DNAemia remained
unchanged with the use of acyclovir or famciclovir. This is similar to findings reported
by Selby et al. [37], Lundgren et al. [38], Ljungman et al. [39], and Prentice et al. [40] who
suggested that acyclovir was ineffective for the prevention of CMV infection. However,
some studies have shown that a high dose of acyclovir might have a protective effect
against CMV among HSCT recipients. Prentice et al. [41] undertook a randomized study
to compare the long-term (one-year) efficacy of acyclovir in three groups: group A (in-
travenous acyclovir 500 mg/m2 given three times/day from day 3 to day 30, then oral
acyclovir 800 mg four times/day from day 31 to 210); group B (intravenous acyclovir
500 mg/m2, three times/day from day 3 to day 30, then placebo from day 31 to day 210);
and group C (oral acyclovir 400 mg, four times/day from day 3 to day 30, then placebo
from day 31 to day 210). Their survival analysis showed a 360-day post-transplant cumu-
lative incidence of CMV viremia of 54% in group A, 50% in group B and 60% in group
C. The difference between group B and group C was statistically significant (p = 0.03).
Meyers et al. [42] studied the efficacy of acyclovir in a cohort of CMV seropositive HSCT
recipients and showed that acyclovir significantly reduced the probability of CMV infection
(0.70% vs. 0.87% p = 0.0001) and CMV disease (22% vs. 38% p = 0.008) after 100 days of
follow-up among the group of patients who received intravenous acyclovir 500 mg/m2
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every 8 h from day 5 to day 30 post-transplant, in comparison to the group which did not
receive acyclovir. Another randomized study by Gluckman et al. [43] on the prophylaxis of
herpesviruses with oral acyclovir 200 mg every 6 h from day 8 to day 35 post-transplant
reported that oral acyclovir was effective against CMV compared to placebo on day 35
(0% vs. 7% p < 0.007). It appears from these studies that the use of high-dose acyclovir
may have a certain effect on CMV. However, despite a possible protective effect noted in
some studies, the number of incident cases of CMV remains high in the exposed groups.
Indeed, at the dose commonly prescribed as prophylaxis for HSV or VZV seropositive
recipients, acyclovir does not appear to influence the incidence of CMV. Our study also
showed no potential impact of famciclovir on CMV. The effect of famciclovir on CMV has
been examined in only one study among adults [44], which showed that CMV reactivation
was higher in seropositive patients who received oral acyclovir or famciclovir (p = 0.0001)
compared to those who received oral valacyclovir and ganciclovir.
In our cohort, the 100-day post-transplant cumulative incidence of EBV DNAemia
was 34.5% (95% CI: 27.6–42.6). This is similar to the cumulative incidence reported in
several studies ranging from 22.6% to 32% in a follow-up period of one to two years among
pediatric HSCT recipients [45–47]. Our study showed no effect of acyclovir or famciclovir
on the incidence of EBV. Hann et al. [48] also found no reduction in the risk of EBV with
the use of acyclovir in a randomized study. Similarly, Paula et al. [49], Krzysztof et al. [50],
and Zutter et al. [51] showed no effect of acyclovir on EBV incidence. To our knowledge,
no study on famciclovir and EBV has been conducted among pediatric HSCT recipients.
However, among children with solid organ transplants, a meta-analysis [52] showed no
significant effect of famciclovir on EBV (adjusted HR = 0.80 (95% CI: 0.42–1.51)).
These results are consistent with the mechanism of action of acyclovir-based anti-
herpesvirus drugs. In their active form, acyclovir and famciclovir are deoxyguanosine
analogs that competitively inhibit herpesvirus DNA polymerase causing arrest of lytic-
cycle viral DNA replication [53]. These drugs have no effect on latent EBV DNA replication
which is dependant on the cellular polymerase, thereby explaining their inefficacy in our
study and in other studies referenced above. In the case of CMV, its lack of a specific
thymidine kinase [53], which converts these drugs to their active form, would explain the
observed lack of effect in clinical trials.
Our study has several strengths and limitations. It is a multicenter study with a
good sample size and external validity. Although we cannot rule out a lack of power
in our results, our cohort is one of the largest prospective studies on EBV outcomes in
pediatric HSCT. However, as with any observational study, residual confounding cannot be
excluded, although we attempted to compensate with rigorous and meticulous adjustment.
Unmeasured variables such as pre-transplant CMV serostatus may also have led to residual
confounding. Furthermore, our study focused on HHV measured by qPCR and did not
distinguish between DNAemia and disease. This must be interpreted accordingly. It is
also difficult to study the effect of different antiviral doses in an observational cohort study.
Exposure to antivirals was analyzed by considering standard doses administered according
to clinical guidelines and monitoring in pediatric HSCT programs. While beneficial effects
of higher acyclovir and famciclovir doses on EBV and CMV may be possible, future
clinical studies should target the effect of other more novel antivirals (such as maribavir)
in pediatric populations. Maribavir is still pending approval (with its last phase III study
completed in August 2020), but may provide some antiviral effect on EBV and CMV [54].
Letermovir is a new CMV inhibitor that targets the viral terminase complex to disrupt CMV
DNA packaging (it was approved by the FDA in November 2017 and by Health Canada in
June 2018 for prevention of clinically significant CMV infection in adult recipients of an
allogeneic stem cell transplant in cases of contraindication or resistance to other antivirals
for prophylaxis against CMV) [55]. Neither of these antivirals are known to impact HSV or
VZV, but there are reports of inhibitory activity against EBV and/or CMV [54,55]. However,
neither maribavir (still pending approval) nor letermovir (approved for CMV prophylaxis
in adults only) was given to patients included in our study. In addition, there are several
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other potentially more promising avenues (such as cytotoxic T lymphocyte (CTL) therapy)
that require further study.
5. Conclusions
Our study suggests a lack of efficacy of antiviral prophylaxis with acyclovir and
famciclovir on EBV and CMV DNAemia in a large cohort of pediatric HSCT recipients.
Prevention of active herpesvirus infections that can cause severe morbidity in HSCT
recipients continues to be crucial to the success of the transplant. Further studies are
needed to better delineate the potential impact of several other novel therapies that could
have a more significant effect on these viruses.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/vaccines9060610/s1, Table S1: Details of EBV and CMV qPCR tests according to study
site, Table S2: Characteristics of hematopoietic stem cell transplant (HSCT) recipients according to
acyclovir and famciclovir use.
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